drugset / Trial / NCT03907657

Contrast-enhanced Ultrasound as a Screening Tool for Kidney Cancer in Patients With Von-Hippel Lindau

NCT03907657

NaSingle-groupOpen-labelDiagnostic

Summary

The purpose of this study is to determine if contrast-enhanced ultrasound can detect abnormal features of kidney lesions in patients with Von-Hippel Lindau with the same accuracy as conventional ultrasound and contrast-enhanced magnetic resonance imaging (MRI)

Timeline

Start
2019-09-23
Primary completion
2023-03-13
Completion
2023-03-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Definity Diagnostic / imaging agent Intravenous
Subject Lumason Diagnostic / imaging agent Intravenous